Evaluation of the In Vitro Efficacy of XXXX and @entity11649 .

@entity5209 @entity4613 @entity6445 @entity11649
UNASSIGNED: The objective of this project is to develop an in vitro approach that can be used to determine the @entity4613 binding capacity of sevelamer @entity5209 and @entity6445 for both drug products and active pharmaceutical ingredients (APIs). A simple and efficient inductively coupled plasma spectrometer method for analysis of @entity4613 at physiologically relevant pH conditions has been developed and validated. The method addresses each of the analytical validation characteristics such as linearity, accuracy, precision, stability, and selectivity, and meets the acceptance criteria defined in the United States Food and Drug Administration guidance (Food and Drug Administration, Center for Drug Evaluation and Research. 2001. Guidance for industry-Bioanalytical method validation, May). The in vitro @entity4613 binding efficacies were systematically evaluated and compared for two drug products and two APIs. The @entity4613 binding profiles appeared similar between the drug products. Under all conditions, the sevelamer- @entity4613 binding reached equilibrium at 6 h. The 90% confidence interval for the k2 ratio (sevelamer @entity6445 vs. @entity11649 ) was well within 80%-125% under all pH conditions. However, the k1 ratio varied, indicating that there exists difference in the binding affinity. Our findings will be useful in assisting with "in vivo" biowaiver for the approval of generic sevelamer drug products.    2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci.
